<!-- Page: 1 -->

## End-to-End AI Framework for Bispecific Antibody Discovery
Generative Models for Multi-Parameter Biologics Optimization

## SECTION 1 - The Challenge: Engineering Complexity

## Instability/Aggregation Issue

![image](https://static-us-img.skywork.ai/prod/nexus/1766127165/cropped_image_3_1766127165781713529.jpg)

> Parameter Optimization Bottleneck

![image](https://static-us-img.skywork.ai/prod/nexus/1766127165/cropped_image_5_1766127165785156483.jpg)

![image](https://static-us-img.skywork.ai/prod/nexus/1766127165/cropped_image_6_1766127165786087997.jpg)

> Conflicting Objectives

## Large Search Space Visualization

![image](https://static-us-img.skywork.ai/prod/nexus/1766127165/cropped_image_9_1766127165791697905.jpg)

## SECTION 2 - Methodology: The Generative Design Loop

![image](https://static-us-img.skywork.ai/prod/nexus/1766127165/cropped_image_11_1766127165796091016.jpg)

> LLMs & Diffusion Models

![image](https://static-us-img.skywork.ai/prod/nexus/1766127165/cropped_image_13_1766127165799820075.jpg)

![image](https://static-us-img.skywork.ai/prod/nexus/1766127165/cropped_image_14_1766127165809287993.jpg)

> 3 Major Obstacles: Stability, Optimization, Search

Iterative AI-driven cycle for rapid, optimized biologics design.

![image](https://static-us-img.skywork.ai/prod/nexus/1766127165/cropped_image_17_1766127165812869099.jpg)

## Structure-Aware Reasoning

![image](https://static-us-img.skywork.ai/prod/nexus/1766127165/cropped_image_19_1766127165814863636.jpg)

> Graph Neural Networks

## Multi-Parameter Screening

Affinity âœ“
Stability âœ“
Solubility âœ“
Aggregation âœ“
Immunogenicity

## SECTION 3 - Results: Validation in Osteogenesis Imperfecta

> Target Success:
TGFB & SOST Targeting

![image](https://static-us-img.skywork.ai/prod/nexus/1766127165/cropped_image_25_1766127165823357312.jpg)

![chart](https://static-us-img.skywork.ai/prod/nexus/1766127165/cropped_image_26_1766127165824994552.jpg)

## Developability Improvements

![chart](https://static-us-img.skywork.ai/prod/nexus/1766127165/cropped_image_28_1766127165828637813.jpg)

## Functional Platform:

> Functional Platform: High-Throughput Screening Validated

![image](https://static-us-img.skywork.ai/prod/nexus/1766127165/cropped_image_31_1766127165831142090.jpg)

![image](https://static-us-img.skywork.ai/prod/nexus/1766127165/cropped_image_32_1766127165831955651.jpg)

> Stability Improvements vs Traditional Fragments

![chart](https://static-us-img.skywork.ai/prod/nexus/1766127165/cropped_image_34_1766127165836044202.jpg)

## SECTION 4 - Impact: Streamlining Biologics Discovery

## Accelerated Timelines

![image](https://static-us-img.skywork.ai/prod/nexus/1766127165/cropped_image_37_1766127165843348706.jpg)

## Manufacturing Alignment

![image](https://static-us-img.skywork.ai/prod/nexus/1766127165/cropped_image_39_1766127165847240524.jpg)

## Reduced Attrition Rates

![image](https://static-us-img.skywork.ai/prod/nexus/1766127165/cropped_image_41_1766127165852469984.jpg)

> AI Framework Significantly Accelerates and De-risks Bispecific Antibody Development.

â˜€ï¸

ALEXION

ğŸ”§

BioClarityAI

<!-- BioClarityAI -->